Has WELL Health Fallen Far Enough? Q2 Results Say the Stock Is Cheaper, but the Smell Test Is Still Tough

At C$3.88, WELL looks discounted, but the stock still carries reasons for caution

At C$3.88, WELL is trading around half the C$7.35 consensus target after a selloff that pushed shares below its 50-day and 200-day moving averages. That makes the stock look cheaper, but not obviously safe. It is reasonable to revisit the name at this level, while still recognizing that debt, integration risk, and comparability issues keep the setup from being a straightforward rebound call.

Bulls will argue the market got too aggressive in resetting expectations. Bears will argue the stock remains cheap for a reason. A balanced view sits somewhere in between: the valuation is more interesting, but the business still needs to prove it can deliver cleaner execution and a cleaner earnings profile.

WELL's operating demand looks real, but the financial story is less clean

Patient traffic and clinic growth support the core demand story

Start with demand. WELL logged 1.9 million patient visits in Q1, up 17% year over year, while Canadian patient services visits grew 33%. Q2 reinforced the momentum in Canada: Canada Patient Services revenue rose 32% to C$151.6 million, and the clinic network reached 275 clinics by quarter-end. That is strong evidence that the Canadian clinic franchise has real traction.

Revenue growth is meaningful, but investors still need to separate the drivers

The scale of the business is clearly expanding. Q1 revenue rose 25% to C$368.3 million, and full-year 2025 revenue reached C$1.40 billion, up 52%. But management has been explicit that growth came from organic expansion, acquisitions, and the inclusion of HEALWELL. Investors should not treat every growth dollar as coming from the same source.

That nuance matters even more after Q2. Revenue grew 12% to C$400.4 million, which is solid, but reported Adjusted EBITDA fell 3% to C$48.1 million because Circle Medical deferrals had lifted the prior-year base by C$9.7 million. In other words, the demand story is getting better support, but the earnings comparability story is still messy.

Canada is the clearest strength; debt is the clearest watchpoint

The strongest part of the model remains Canada. In Q2, Canadian Patient Services Adjusted EBITDA rose 22% to C$22.3 million, and management said the Canada business reached an annualized Adjusted EBITDA run-rate above C$100 million. Those are tangible signs that the clinic network is becoming more than just a growth narrative.

Still, the capital structure keeps the smell test from being fully clean. WELL closed a C$150 million senior unsecured notes due 2031 at 6.875% to repay its convertible debentures due in December 2026. That improves the maturity profile, but it does not make WELL a simple deleveraged compounding story. If Canada keeps compiling visit growth, clinic growth, and profitability, the debt can be framed as funding real expansion. If execution wobbles, the higher leverage matters more.

Has it fallen far enough? Only if Canada keeps offsetting the US and execution noise

What the recent selloff likely priced in

The recent decline clearly made the stock cheaper. After a 7.4% intraday drop to C$3.88 and a move below the 50-day average of C$4.11 and 200-day average of C$4.38, the market is showing fresh skepticism. Analyst sentiment is still split, with 4 BUY recommendations against 3 SELLs and the latest listed as WATCH. That is not the kind of consensus that usually forces fast recap. It does, however, leave room for a move if the company starts delivering clearer proof.

What would need to happen for a rerating

WELL does not need a dramatic new story. It needs Canada to keep doing enough of the heavy lifting that investors focus less on financing risk and more on operating momentum. Management has already set a baseline: C$1.55 billion to C$1.65 billion in 2026 revenue and C$175 million to C$185 million in 2026 Adjusted EBITDA. If those ranges hold up, investors have a workable benchmark for execution.

Free cash flow also helps the case that this is not a business operating without a buffer. WELL generated C$58.2 million of 2025 free cash flow, which suggests operations can buy time for integration and cleanup. The company did not report the Q1 cash-flow figure cited in the earlier draft, so that point should be tied only to the verified 2025 number.

What would strengthen the bull case, and what would break it

Watch for a short list of practical proof points: - guidance remains firm and gains credibility - Canada continues to deliver visit, clinic, and profitability growth - profitability trends improve once comparability issues fade - cash flow stays strong enough to support integration without added stress

That makes WELL a watchlist name that could turn into a small position if those signals start to align, rather than an automatic rebound trade. The thesis weakens if guidance stops mattering, Canadian momentum fades, or cash flow becomes less reliable.